Tg Therapeutics, Inc.

This study follows 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI, a medication given by infusion. Researchers want to see how well it works and what side effects occur in everyday medical practice, not just in a controlled trial. Participants must not h…

This study tests a modified dosing schedule of ublituximab, a drug that targets certain immune cells, in 800 people with relapsing multiple sclerosis (MS). The goal is to see if the new regimen reduces brain lesions (spots of inflammation) better than current approaches. Particip…

This early-phase study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis. About 100 adults will receive this cell therapy to find the safest dose and see if it can control disease activit…

This study looks at how much of the multiple sclerosis drug BRIUMVI gets into breast milk. Researchers will collect milk samples from 16 breastfeeding women who already take BRIUMVI for relapsing MS. The goal is to understand drug exposure for nursing infants, not to test a new t…

This study observes pregnant women with multiple sclerosis to compare the rate of major birth defects between those who took BRIUMVI and those who did not. About 728 participants will provide data during and after pregnancy. The goal is to gather safety information, not to test a…